Seegene Unveils Groundbreaking CURECA™: A New Era in Fully Automated PCR Technology

Seegene Unveils CURECA™: The Future of PCR Testing

On April 16, 2025, at the prestigious ESCMID Global 2025 conference held in Vienna, Seegene Inc., a global pioneer in molecular diagnostics, revealed its latest innovation: CURECA™. This next-generation fully automated PCR system is designed to facilitate every step of the PCR process, from sample pre-treatment to result analysis.

CURECA™, which stands for Continuous Unlimited Random access Expandable and Customizable full Automation, epitomizes Seegene's commitment to advancing laboratory automation and setting a new global standard in the realm of molecular diagnostics. The system is engineered to operate continuously with minimal human intervention, aligning with Seegene's vision for a world free from diseases.

Revolutionary Automation in Laboratory Testing

Seegene's CURECA™ is anticipated to streamline and enhance the efficiency of PCR testing. It consists of two key components: the Customizable Preprocessing System (CPS) and the Customizable and Expandable Full Automation (CEFA). The CPS automates critical initial steps, including sample insertion and preliminary processing, while the CEFA focuses on sample preparation for nucleic acid extraction, PCR setup, gene amplification, and results analysis.

Historically, the preliminary phase of molecular diagnostics has depended heavily on the meticulous handling of various sample types—blood, urine, stool, and sputum—often requiring skilled laboratory personnel for tasks that include sorting samples and preparing the appropriate containers. This manual approach frequently introduces the possibility of human error into the testing process.

With the CPS, Seegene proposes a transformative solution, automating crucial operations such as sample sorting, centrifugation, mixing, and thermal processing. This modular system not only improves the efficiency of PCR testing but is also applicable to other laboratory areas like hematology, biochemistry, and immunodiagnostics, thereby broadening its utility in clinical practices.

Modular Design for Tailored Laboratory Solutions

The modular architecture of CURECA™ allows laboratories to configure the system according to their specific operational requirements. By automating the entire PCR testing procedure, the system aims to significantly reduce human error and bolster high-throughput testing capabilities.

Seegene's video presentation at the ESCMID conference showcased the complete workflow automation—from sample insertion to nucleic acid extraction, PCR configuration, gene amplification, and results analysis. The presentation underscored CURECA™'s adaptability to diverse laboratory environments and testing capacities, reinforcing Seegene's intention to enable efficient, reliable, and scalable diagnostics.

A Vision for a Disease-Free World

Dr. Jong-Yoon Chun, the founder and CEO of Seegene, remarked, "There has never been a system capable of fully automating the preparation of all sample types, which has hindered true automation in molecular diagnostics. Our goal is to establish a new global standard and shape the future of MDx."

CURECA™ also supports Seegene's broader global initiative in technology sharing, aspiring to make advanced MDx methods accessible and integrate them better into everyday healthcare systems worldwide. Dr. Chun emphasized, "CURECA™ marks the first step toward realizing our vision of a world free of diseases. We remain committed to leading innovation and global collaboration to achieve this vision."

Redefining Molecular Diagnostics

At the ESCMID 2025 conference, Seegene presented its portfolio of real-time PCR syndromic tests, including solutions currently in use to combat antimicrobial resistance and address evolving diagnostic needs in the post-COVID-19 landscape. Notable products such as the Entero DR test and STI-AMR test were featured in discussions about informed and timely treatment decisions.

With over 20 years of experience in research, development, manufacturing, and distribution within the realm of real-time PCR syndromic technologies, Seegene has demonstrated its expertise, especially during the COVID-19 pandemic. The company distributed over 340 million tests to more than 100 countries, showcasing its capability to deliver reliable testing solutions efficiently.

Visit Seegene.com and follow their updates on LinkedIn to learn more about their groundbreaking innovations and initiatives for a healthier world.